Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A.

N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

2.

A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT.

Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.

PMID:
28934680
3.

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Verstovsek S.

Postgrad Med. 2013 Jan;125(1):128-35. doi: 10.3810/pgm.2013.01.2628. Review.

4.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G.

N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.

5.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

6.

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Bryan JC, Verstovsek S.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26. Review.

7.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S.

Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3.

8.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S.

Blood. 2010 Feb 11;115(6):1131-6. doi: 10.1182/blood-2009-10-246363. Epub 2009 Dec 11.

9.

Ruxolitinib.

Becker H, Engelhardt M, von Bubnoff N, Wäsch R.

Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. Review.

PMID:
24756798
10.

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z, Dölemeyer A, Dammassa E, Sterker D, Cozens R, Hofmann F, Murakami M, Baffert F, Radimerski T.

Clin Cancer Res. 2013 Nov 15;19(22):6230-41. doi: 10.1158/1078-0432.CCR-13-0905. Epub 2013 Sep 30.

11.

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.

DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN.

Br J Haematol. 2013 Aug;162(3):326-35. doi: 10.1111/bjh.12384. Epub 2013 May 23.

PMID:
23701016
12.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Cancer. 2014 Feb 15;120(4):513-20.

13.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM.

N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.

14.

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Ostojic A, Vrhovac R, Verstovsek S.

Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.

15.

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.

Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S.

Cancer. 2011 Nov 1;117(21):4869-4877. doi: 10.1002/cncr.26129. Epub 2011 Apr 8.

16.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

PMID:
25171702
17.

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S.

Blood. 2015 Sep 24;126(13):1551-4. doi: 10.1182/blood-2015-03-635235. Epub 2015 Jul 30.

18.

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.

Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P, Hertel D, Haley P, Lo Y, Waeltz P, Rodgers J, Shepard S, Vaddi K, Yeleswaram S, Levy R, Williams W, Gottlieb AB.

Br J Dermatol. 2015 Oct;173(4):989-97. doi: 10.1111/bjd.13994. Epub 2015 Oct 14.

PMID:
26123031
19.

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.

Quintás-Cardama A, Verstovsek S.

Cancer. 2012 Feb 15;118(4):870-7. doi: 10.1002/cncr.26359. Epub 2011 Jul 15.

20.

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.

Kirabo A, Park SO, Wamsley HL, Gali M, Baskin R, Reinhard MK, Zhao ZJ, Bisht KS, Keserű GM, Cogle CR, Sayeski PP.

Am J Pathol. 2012 Sep;181(3):858-65. doi: 10.1016/j.ajpath.2012.05.033. Epub 2012 Jul 13.

Supplemental Content

Support Center